Edwards Lifesciences (NYSE:EW) shares hardly moved after hours on third-quarter results that came in ahead of the consensus forecast. The Irvine, Calif.-based company posted profits of $325.2 million, or 52¢ per share, on sales of $1.14 billion for the three months ended Sept. 30, 2020, for an 18.4% bottom-line gain on sales growth of 4.3%. Adjusted […]
Cardiovascular
Abbott beats the Street in Q3, projects higher full-year sales
Abbott (NYSE:ABT) posted stronger-than-expected third-quarter earnings today and upped its full-year projections. The Abbott Park, Ill.-based healthcare giant reported profits of $1.232 billion or 98¢ per share for the quarter ended Sept. 30, 2020, led by a whopping 38.2% increase in global diagnostics sales and a 27% sales jump for diabetes care devices. Analysts had projected […]
FDA clears Aidoc triage of incidental pulmonary embolism
Aidoc announced today that it received FDA clearance for the commercial use of its triaging algorithms for pulmonary embolism. New York-based Aidoc’s triaging and notification algorithms designed to flag and communicate incidental pulmonary embolism offers increased efficiency in prioritizing incidental critical conditions through artificial intelligence (AI), according to a news release. The technology offers an […]
3M and Eko collaborate on stethoscopes
3M (NYSE:MMM) and Eko announced today that they are collaborating to combine 3M’s Littmann stethoscope with Eko’s digital innovations. St. Paul, Minn.-based 3M’s new Littmann CORE digital stethoscope includes capabilities for clinicians to access both analog and digital auscultation options, along with amplification and noise cancellation and the visualization of sound during auscultation. 3M and Oakland, Calif.-based Eko […]
MedTech 100 roundup: Industry continues its ascent
Stocks in the medtech industry maintained their upward trajectory, topping last week’s peak with yet another rise to new heights. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 95.66 (Oct. 16), marking a 0.6% gain from the 95.05 points registered at the end of […]
The top 5 MassDevice stories of the week — October 16, 2020
For the second consecutive week, medtech giant Medtronic (NYSE:MDT) managed to dominate the news on MassDevice. The company’s “Investor Day” brought about several headlines, including new clinical trials ahead and a rallying cry from CEO Geoff Martha. Other news that garnered some attention came in the form of a new ultrasound system from another big player […]
Livmor wins FDA nod for continuous heart monitoring wearable
Livmor announced today that it received FDA 510(k) clearance for its Livmor Halo wearable AFib detection system. Dallas-based Livmor’s Halo AFib detection system is a physician-prescribed wearable device for continuously monitoring pulse rhythms to detect AFib on-demand during the day and automatically overnight, according to a news release. Halo is deployed on a Samsung wearable […]
Boston Scientific shares slide on TAVR study results
Shares in Boston Scientific (NYSE:BSX) slid nearly 4% on news that the rates of cardiac death in patients implanted with its Acurate Neo heart valve were significantly higher than those in patients who received Medtronic’s (NYSE:MDT) CoreValve Evolut. The head-to-head SCOPE II study, presented today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation, […]
Philips touts post-stent imaging study results
Royal Philips (NYSE:PHG) announced today that one-year results of its Define PCI study that reported improved outcomes and less recurrent angina. The Define PCI study assessed the level of residual ischemia found in patients following a percutaneous coronary intervention (PCI) using a blinded instant wave-free ratio (iFR) pullback measurement, which is a guidance technology unique to […]
Abbott touts Xience DES study results
A pair of studies of Abbott’s Xience drug-eluting stent showed no difference between shorter courses of treatment with dual antiplatelet therapy (DAPT) compared with 12 months of DAPT following implantation of the XIENCE drug-eluting stent (DES) in patients who are at a high risk of bleeding. Abbott presented the late-breaking data today at TCT Connect, […]
Abiomed touts latest Impella trial results
Abiomed (NSDQ:ABMD) today announced interim results of a study that found high-risk patients had better outcomes after implantation with its Impella CP heart pump. Data from the PROTECT III FDA post-approval study of Impella 2.5 and Impella CP in high-risk percutaneous coronary intervention (PCI) patients showed reduced rates of MACCE — a composite of death, stroke, […]
